Moderna raised its 2026 revenue growth outlook to 15% to 25%, up from its previous guidance of up to 10%. The biotech company reported the update on Friday along with third-quarter results that beat analyst estimates. Shares rose roughly 3% in premarket trading.

Third-quarter revenue jumped 29% to $1.31 billion. Revenue was $780 million in the U.S. and $533 million in international markets. The company posted net income of $162 million, or 38 cents per share, compared with a net loss of $200 million, or 51 cents per share, a year earlier.

CEO Stéphane Bancel credited newer products and geographic diversification for the quarter. He said Moderna is seeing the "full-year impact" of its next-generation mRNA Covid vaccine, which won U.S. approval in May 2025. He said the vaccine had only a "small launch" last year because Covid vaccine contracts are typically set in the first quarter. Bancel also said the new stand-alone flu shot, approved in the U.S. in August, will have a "limited launch" in the country in 2026. In a CNBC interview, he attributed the results to geographic expansion in Canada, the U.K. and Asia, and to cost reductions. "It's the sales that are stronger and the costs that are also lower," he said.

Bancel said the company's results come weeks after Moderna and Merck released late-stage data on an experimental personalized cancer vaccine, used with the immunotherapy Keytruda, in certain melanoma patients. He said part of that data was leaked on social media days before it was to be presented at a European medical conference, and that investors reacted negatively. He called the reaction a "surprising reaction." He said long-term investors and analysts who reviewed the full data responded positively, and that doctors "were so impressed with the data."